PLAY PODCASTS
BioSpace

BioSpace

BioSpace

272 episodesEN

Show overview

BioSpace has been publishing since 2023, and across the 3 years since has built a catalogue of 272 episodes. That works out to roughly 90 hours of audio in total. Releases follow a several-times-a-week cadence.

Episodes typically run ten to twenty minutes — most land between 16 min and 23 min — though episode length varies meaningfully from one episode to the next. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Science show.

The show is actively publishing — the most recent episode landed yesterday, with 84 episodes already out so far this year.

Episodes
272
Running
2023–2026 · 3y
Median length
19 min
Cadence
Several per week

From the publisher

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Latest Episodes

View all 272 episodes

Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

Oct 7, 202624 min

The race for access: How the FAIR Act could reclaim U.S. biotech leadership

Oct 1, 202620 min

AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

Sep 30, 202620 min

How radioligand therapy is rewriting cancer care

Sep 24, 202615 min

Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz

Sep 23, 202621 min

When vision fades: Rethinking wet AMD and the durability gap

Sep 17, 202621 min

FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival

Sep 16, 202622 min

The supply chain fault lines of modern pharma

Sep 10, 202636 min

Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease

Sep 9, 202620 min

Breaking borders: Building biotech scale in Benelux

Sep 3, 202618 min

Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals

Sep 2, 202620 min

Fragile X at a turning point: Breaking through the clinical bottleneck

Aug 27, 202619 min

Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed

Aug 26, 202623 min

Rewriting the rules of CMV prevention

Aug 20, 202619 min

Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

Aug 19, 202619 min

The Italian inflection point: Clinical strength, culture and capital

Aug 13, 202618 min

Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

Aug 12, 202619 min

Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

Aug 11, 202623 min

The next treatment-resistant depression paradigm

Aug 6, 202620 min

Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

Aug 5, 202624 min
2026 BioSpace